CDMO
Avid Bioservices, Inc. Common Stock
stock NASDAQ

\*\*Yes, you read that right\*\*
Propanc Biopharma authorized a share repurchase roughly the size of its own market cap. Same morning: a CDMO deal to manufacture trial material for a Phase 1b that hasn't even been filed yet. Preclinical company, zero revenue. The headlines were real, the proportions were not.
\*\*The tape\*\*
Stock Pulse pinged it premarket at 8:36, $2.76. It climbed through the bell and printed $6.79 at 10:15, up 146% in 99 minutes. Then the slow bleed: closed $2.42, twelve percent under the alert.
\*\*Why it could move that hard\*\*
Float is about 1.6M shares after last month's 1-for-25 reverse split. Around 173M shares traded. Premarket high was already +366% over the prior close before most people had coffee.
\*\*Track record\*\*
Did a 1-for-250 reverse split in 2017. Did the 1-for-25 in May. The 52-week "high" of $270 is just split math on a stock that was nine cents in April.
\*\*Bottom line\*\*
Catalyst was real, size was nano, fade was total. Post-mortem only — this round trip is finished.

Conexeu Sciences Inc. feels like they are starting to hit some of the milestones that matter beyond the science. Latest PR was focused on their lead wound care product, Ten Minute Tissue which is built on the company's proprietary extracellular matrix platform. As far as i understood, they have now successfully transferred manufacturing methods to their CDMO partner and are producing material for the final phases of regulatory testing.
Might not sound exciting on the surface but it does suggests the company is moving from a research-stage operation toward something that could eventually support commercial production.
Another thing that caught my attention was the feedback they received from the FDA through the Q-Submission process. From what I understand, this gives companies a chance to align their testing plans and documentation with regulators before submitting the full application. It doesn't guarantee approval, but it can help avoid surprises later in the review process.
Management is targeting a 510k submission in Q1 2027 so there is still work ahead, but having a clearer regulatory path is generally something investors like to see. Also they completed Nasdaq listing in late May, thats always a big deal and thats how you get bigger eyes on the stock with institutional access ofc
what do you guys think??

\*\*Yes, you read that right\*\*
Propanc Biopharma authorized a share repurchase roughly the size of its own market cap. Same morning: a CDMO deal to manufacture trial material for a Phase 1b that hasn't even been filed yet. Preclinical company, zero revenue. The headlines were real, the proportions were not.
\*\*The tape\*\*
Stock Pulse pinged it premarket at 8:36, $2.76. It climbed through the bell and printed $6.79 at 10:15, up 146% in 99 minutes. Then the slow bleed: closed $2.42, twelve percent under the alert.
\*\*Why it could move that hard\*\*
Float is about 1.6M shares after last month's 1-for-25 reverse split. Around 173M shares traded. Premarket high was already +366% over the prior close before most people had coffee.
\*\*Track record\*\*
Did a 1-for-250 reverse split in 2017. Did the 1-for-25 in May. The 52-week "high" of $270 is just split math on a stock that was nine cents in April.
\*\*Bottom line\*\*
Catalyst was real, size was nano, fade was total. Post-mortem only — this round trip is finished.

Conexeu Sciences Inc. feels like they are starting to hit some of the milestones that matter beyond the science. Latest PR was focused on their lead wound care product, Ten Minute Tissue which is built on the company's proprietary extracellular matrix platform. As far as i understood, they have now successfully transferred manufacturing methods to their CDMO partner and are producing material for the final phases of regulatory testing.
Might not sound exciting on the surface but it does suggests the company is moving from a research-stage operation toward something that could eventually support commercial production.
Another thing that caught my attention was the feedback they received from the FDA through the Q-Submission process. From what I understand, this gives companies a chance to align their testing plans and documentation with regulators before submitting the full application. It doesn't guarantee approval, but it can help avoid surprises later in the review process.
Management is targeting a 510k submission in Q1 2027 so there is still work ahead, but having a clearer regulatory path is generally something investors like to see. Also they completed Nasdaq listing in late May, thats always a big deal and thats how you get bigger eyes on the stock with institutional access ofc
what do you guys think??